The CREDIT project was initiated in 2016. It is a non-interventional multicentre retrospective and prospective longitudinal study of patients with inflammatory bowel disease (IBD) who have been treated with biological and innovative therapies.

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, typically affecting young people (aged 15 to 30). Crohn’s disease and ulcerative colitis are the principal types of IBD. Inflammatory bowel disease is rather difficult to manage, and often significantly affects the patients’ quality of life, including their work life and social activities. After exhausting all possibilities of conservative drug treatment (aminosalicylates, corticosteroids, immunosuppressive drugs), IBD patients are indicated for the administration of biological or innovative therapies. Biological and innovative therapy is the most effective option for IBD treatment, and is usually administered over long periods of time. In the Czech Republic, biological and innovative therapy for IBD treatment is administered in specialised centres.

Information obtained in this project can significantly contribute to improvements in the effectiveness and safety of biological and innovative therapy for IBD.

Primary objective of the project:

To monitor the overall number of IBD patients treated with biological and innovative therapies in the Czech Republic.

Secondary objectives of the project:

Assessment of effectiveness of biological and innovative therapies, assessment of safety of biological and innovative therapies, assessment of therapeutic regimens, monitoring of duration of biological and innovative therapy in IBD patients.